Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram?
OBJECTIVE Comparing the antidepressant effects of Citalopram with Fluoxetine and their effect on glycemic control in diabetic patients . METHODS Forty patients attending the Diabetes Research Center in Kermanshah University of Medical Sciences , Kermanshah , Iran from September 2006 to October 2007 with type II diabetes and suffering from major depression were r and omly assigned to 2 groups ( n=20 per group ) in a r and omized controlled trial method . They received up to 40 mg/d of Fluoxetine or Citalopram . Twelve weeks after treatment , patients were reassessed in terms of severity of depression and diabetic status . The Beck Depression Inventory ( BDI ) and psychiatric interview  were used to measure the severity of depression and follow up the patients . Glycosylated hemoglobin ( HbA1c ) levels and fasting blood sugar ( FBS ) was obtained to monitor glycemic control . RESULTS After the 12-week treatment , both groups showed significant improvement in severity of depression , FBS , and HbA1c . There were no significant differences between the 2 groups in terms of improvement in depression and diabetic status . CONCLUSION Fluoxetine and Citalopram can effectively reduce the severity of depression in diabetic patients without an adverse effect on glycemic control
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .